Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hawaii
Clinical trial register · United States · industry-sponsored

Clinical Trials in Hawaii, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 151 Florida 150 Arizona 96 Georgia 89 Illinois 70
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in Hawaii

18 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa
2026-02-06
Active, closed
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415Obesity, Overweight
Eli Lilly and Company
Phase 3
600
Arizona, California, Florida, Hawaii, Kentucky, Massachusetts, Michigan, New York
2026-01-24
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895Type 1 Diabetes, Obesity, Overweight
Eli Lilly and Company
Phase 3
905
California, Colorado, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa
2025-04-25
Active, closed
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268Obesity
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Active, closed
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383Obesity
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2024-11-01
Active, closed
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728Obesity, Overweight
Eli Lilly and Company
Phase 2
252
Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington
2024-10-21
Active, closed
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Diabetes Mellitus, Type 2
Eli Lilly and Company
Phase 3
1,250
Alabama, California, Colorado, Florida, Georgia, Hawaii, Idaho, Indiana
2024-02-21
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956Obesity, Overweight
Eli Lilly and Company
Phase 2
1,481
Arizona, California, Connecticut, Florida, Hawaii, Idaho, Illinois, Iowa
2023-11-17
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
Eli Lilly and Company
Phase 3
3,127
Arizona, California, Colorado, Florida, Georgia, Hawaii, Idaho, Kansas
2023-06-05
Active, closed
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512Obesity, Overweight
Eli Lilly and Company
Phase 3
15,374
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2022-10-11
Active, closed
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
NCT05169567Breast Neoplasm, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
368
Arizona, Arkansas, California, Colorado, Florida, Georgia, Hawaii, Illinois
2022-03-11
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Arizona, California, Colorado, Florida, Hawaii, Illinois, Indiana, Kentucky
2021-10-04
Active, closed
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448Metastatic Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 3
545
California, Colorado, Hawaii, Kansas, New York, North Carolina, Pennsylvania
2015-05-06
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/state/hawaii

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Hawaii that also match the filters currently applied.

How many clinical trials are recruiting in Hawaii?

4 of the 18 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 14 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hawaii), 18 studies
PhaseStudiesRecruitingShare
Phase 316388.9%
Phase 22111.1%

Most active sponsors

Lead sponsors with the most studies (Hawaii)
Lead sponsorStudiesRecruiting
Eli Lilly and Company184
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.